Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of AAPB injection for acute ischemic stroke
ChiCTR2600124827Phase 2Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- May 2026
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 2-aminoethoxydiphenylborate in brain infarction (4 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Proportion of participants with mRS ≤ 1 at 90 days. Planned start May 2026; status: not yet recruiting.
02
Drugs
2-aminoethoxydiphenylborate
03
Conditions
brain infarction
Beyond the preview
Go deeper on ChiCTR2600124827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124827.